Search
Displaying 451–460 of 689 for “retinitis clinical trial”
-
Age-Related Macular Degeneration
DiseaseAge-related macular degeneration, or AMD, is the leading cause of blindness in people 55 and older in developed countries. The condition can lead to significant loss of central vision.
-
Foundation Commits $2 Million to Development of a Cross-Cutting Drug Treatment
NewsMitoChem Therapeutics has identified three compounds that appear to boost mitochondrial function and, thus, show potential for slowing vision loss caused by a variety of retinal degenerations.
-
Invisible Disability
I find it difficult to explain my eyesight to people. I have retinitis pigmentosa (RP), which is a condition that progressively causes vision loss. I am legally blind, my peripheral vision is very limited, and most of what I see is blurry.
-
Research News
The five-year grant will advance the emerging treatments toward clinical trials
-
Research News
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
-
Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
Foundation NewsThe project will help identify outcome measures for future clinical trials of potential USH1F therapies.
-
Beacon Stories
Jenny was diagnosed with retinitis pigmentosa (RP), just like her mom, at the age of 34. In her own words, Jenny shares her experience with being diagnosed with RP and her journey to accepting it with hopefulness.
-
Preclinical and Translational Research Webinar Series
Odylia Therapeutics and the Foundation Fighting Blindness have teamed up to hold a four (4) part preclinical and translational research webinar series. This series will focus on genetic technologies for blinding diseases and will provide tangible advice and educational materials to researchers in the inherited retinal disease (IRD) space.
-
In the Press
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
-
Brint Family Translational Research Award
The Brint Family Translational Research Program awards will accelerate the movement of preclinical research toward an Investigational New Drug filing and into clinical trials to provide a robust and diverse pipeline of potential therapies to fight inherited retinal degenerations (IRD) and dry age-related macular degeneration.
